Exenatide

The first GLP-1 receptor agonist approved for type 2 diabetes, derived from exendin-4 in Gila monster venom.

What research shows

Exenatide was the first licensed GLP-1 receptor agonist, developed from exendin-4 found in Gila monster venom. Randomized comparative trials show improved glycaemic control, and pooled analyses show weight reduction. It is a licensed medicine with decades of trial evidence behind it.

Evidence strength

Highest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.